AbCellera Biologics Inc vs iShares Global Tech ETF — how do they compare? AbCellera Biologics Inc trades at $9.96 (market cap $2.99B), while iShares Global Tech ETF trades at $142.44. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | IXN | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $149.74 |
52-Week Low | $2.78 | $94.42 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
No Aura AI signal available yet.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →